Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5438708 | 0.92 | CXCR2 (0.72) | CXCR2 | |
| SCHEMBL4587175 | 0.86 | CXCR2 (0.58) | CXCR2 | |
| SCHEMBL1562925 | 0.85 | CXCR2 (1.00) | CXCR2 | |
| Hydrochloric Acid SCHEMBL4355911 | 0.84 | CXCR2 (0.98) | CXCR2 | |
| SCHEMBL12662164 | 0.83 | CXCR2 (0.69) | CXCR2 | |
| SCHEMBL13096283 | 0.82 | CXCR2 (0.79) | CXCR2 | |
| Elubrixin SCHEMBL1562280 | 0.81 | CXCR2 (1.00) | CXCR2 | |
| Elubrixin SCHEMBL30515706 | 0.81 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL10077611 | 0.81 | CXCR2 (0.58) | CXCR2 | |
| SCHEMBL1562893 | 0.81 | CXCR2 (0.79) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2034832-B1 | IL-8 RECEPTOR ANTAGONIST | GLAXOSMITHKLINE LLC (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2388006-A1 | Urea derivatives as IL-8 receptor antagonists | GlaxoSmithKline LLC (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110253866-A1 | SWINGING SUPPORT DEVICE | PANASONIC CORPORATION (JP) | 2011-10-20 | — | — | US | disclosed |
| EP-1558259-B1 | Urea derivatives as IL-8 receptor antagonists | GLAXOSMITHKLINE LLC (US) | 2011-04-06 | — | — | EP | disclosed |
| US-20100256157-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256157-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2010-10-07 | — | — | US | disclosed |
| US-7709485-B2 | IL-8 receptor antagonists | GLAXOSMITHKLINE LLC (US) | 2010-05-04 | — | — | US | disclosed |
| US-20090281110-A1 | Method of Treatment | SMITHKLINE BEECHAM CORPORATION | 2009-11-12 | — | — | US | disclosed |
| US-20090281110-A1 | Method of Treatment | SMITHKLINE BEECHAM CORPORATION | 2009-11-12 | — | — | US | disclosed |
| US-20090170871-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090093492-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION | 2009-04-09 | — | — | US | disclosed |
| WO-2009039091-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2007150015-A2 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007150016-A2 | IL-8 RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20060040952-A1 | Il-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256157-A1 | METHOD OF TREATMENT | CFTR, CTH, TST | CXCR2 794/4885 |
| US-20060040952-A1 | Il-8 receptor antagonists | CXCL8, CCR8, IL1RN | CXCR2 9/4885 |
| US-20090093492-A1 | IL-8 RECEPTOR ANTAGONISTS | CXCL8, CCR8, IL1RN | CXCR2 9/4885 |
| US-20090281110-A1 | Method of Treatment | ESR2, CTH, SULT2A1 | CXCR2 2176/4885 |
| US-20090170871-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | CXCR2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.